Metrics as of 10/17/2026, 12:06 AM (Berlin time), refresh in progress.
Sarepta Therapeutics Stock
Sarepta Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael E. Severino
- Employees
- 835
- Market cap
- $1.8 B
- IPO
- 04/06/1997
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company based in the US that focuses on the discovery and advancement of genetic treatment modalities. Its work includes RNA-targeted therapeutics and gene therapies specifically designed for rare diseases. Headquartered in Cambridge, the company…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Sarepta Therapeutics stock: price history
1D
-3.9%
1W
-4.2%
1M
-13.5%
6M
-20.6%
YTD
-20.5%
1Y
-26.7%
2Y
-86.4%
5Y
-79.7%
10Y
-67.3%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~26% stronger price swings than usual
Ask the agents about Sarepta Therapeutics
Analyst assessment of Sarepta Therapeutics
PRICE TARGET LOW
US$17.00
CONSENSUS
US$21.60
MEDIAN
US$20.00
PRICE TARGET HIGH
US$27.00
0
STRONG BUY
31
BUY
18
HOLD
6
SELL
0
STRONG SELL
55
TOTAL · Buy
As of: 08/10/2026
Sarepta Therapeutics stock metrics
P/E
-11.87
P/B
1.18
EV/EBITDA
-156.4
RETURN ON EQUITY
-0.3%
NET MARGIN
-1.2%
DEBT/EQUITY
0.68
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.1%
FLOAT SHARES
100,445,362
AVG. DAILY VOLUME (30D)
3,165,347
Insider transactions (SEC)
Rodino-Klapac Louise
Rothfuss Cristin
Estepan Ian Michael
Wong Ryan Ho-Yan
SEVERINO MICHAEL
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.9%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Sarepta Therapeutics stock
What does Sarepta Therapeutics do?
Sarepta Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael E. Severino, the company employs around 835 people.
The IPO was on 04/06/1997; the stock trades on NASDAQ under the ticker SRPT.
What do analysts say about Sarepta Therapeutics stock?
55 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$21.60, ranging from US$17.00 to US$27.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Sarepta Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 26% stronger than usual.
Does Sarepta Therapeutics pay a dividend?
No, Sarepta Therapeutics currently does not pay a dividend.
Which stocks are comparable to Sarepta Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Sarepta Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sarepta Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.